Singh Avinash Kumar, Kumar Anoop, Agrawal Narendra, Bhurani Dinesh, Ahmed Rayaz, Sharma Manju
Department of Pharmaceutical Medicine (Division of Pharmacology), School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi-110062, India.
Department of Hemato-Oncology & BMT Unit, Rajiv Gandhi Cancer Institute, and Research Centre, Sector - 5, Rohini, Delhi-110085, India.
Curr Rev Clin Exp Pharmacol. 2023;18(2):148-157. doi: 10.2174/2772432817666220315144253.
Imatinib is one of the tyrosine kinase inhibitors used for the treatment of chronic myeloid leukemia (CML) patients. The exact association of imatinib with anemia in CML patients is still unclear.
The current study aimed to find the prevalence of anemia in chronic myeloid leukemia patients treated with imatinib.
The relevant articles were searched in PubMed, Google scholar, and Clinical trials registries till 31st July, 2021. The quality of the articles was assessed using the Newcastle-Ottawa Scale. The prevalence rate with 95% CI was calculated using StatsDirect Statistical analysis software V.3.
A total of 18 studies containing 3537 patients were found relevant for the analysis. The pooled prevalence of anemia in CML was found to be 34% (95% CI: 23%-46%). However, the heterogeneity among studies was found to be high.
The monitoring of hemoglobin levels and identifying the cause of anemia are major concerns for the CML patients treated with Imatinib.
伊马替尼是用于治疗慢性粒细胞白血病（CML）患者的酪氨酸激酶抑制剂之一。伊马替尼与CML患者贫血的确切关联仍不清楚。
本研究旨在确定接受伊马替尼治疗的慢性粒细胞白血病患者贫血的患病率。
在PubMed、谷歌学术和临床试验注册库中检索截至2021年7月31日的相关文章。使用纽卡斯尔-渥太华量表评估文章质量。使用StatsDirect统计分析软件V.3计算95%置信区间的患病率。
共发现18项研究，包含3537例患者，适合进行分析。CML患者贫血的合并患病率为34%（95%置信区间：23%-46%）。然而，研究之间的异质性较高。
监测血红蛋白水平并确定贫血原因是接受伊马替尼治疗的CML患者的主要关注点。
